Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 3/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL596921 | 0.88 | PER2 (0.38) | PER2CRY2ALDH1A1MAPTPIK3CD | |
| SCHEMBL1106515 | 0.85 | BRD4 (0.39) | PER2CRY2ALDH1A1MAPTPIK3CD | |
| SCHEMBL24687997 | 0.80 | BRD4 (0.39) | PER2CRY2ALDH1A1MAPTPIK3CD | |
| SCHEMBL13918278 | 0.80 | PER2 (0.43) | PER2CRY2PIK3CDLMNACA12 | |
| SCHEMBL19443027 | 0.80 | PER2 (0.36) | PER2CRY2PIK3CD | |
| SCHEMBL19872806 | 0.79 | PER2 (0.42) | PER2CRY2PIK3CDLMNACA12 | |
| SCHEMBL23714591 | 0.79 | NPY5R (0.38) | PER2CRY2 | |
| SCHEMBL24848139 | 0.77 | PER2 (0.33) | PER2CRY2ALDH1A1MAPT | |
| SCHEMBL25703614 | 0.77 | PER2 (0.33) | PER2CRY2ALDH1A1MAPT | |
| SCHEMBL26141151 | 0.77 | MAPK1 (0.38) | PER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-10179793-B2 | ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2017075056-A1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-05-04 | — | — | WO | disclosed |
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1054297-A1 | PHOTORESIST STRIPPER AND METHOD OF STRIPPING | Clariant International Ltd. (CH) | 2000-11-22 | — | — | EP | disclosed |
| US-4918186-A | Process for producing cyclic ureas | MITSUI TOATSU CHEMICALS, INC. (JP) | 1990-04-17 | — | — | US | disclosed |
| EP-0248220-A2 | Process for producing cyclic ureas | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145028-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | PER2 4070/4885CRY2 4373/4885ALDH1A1 104/4885 |
| US-10179793-B2 | ACC inhibitors and uses thereof | ACACA, ACACB, ACAT2 | PER2 4070/4885CRY2 4373/4885ALDH1A1 104/4885 |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | NR2C2, NR0B2, NR3C2 | PER2 741/4885CRY2 369/4885ALDH1A1 3967/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | PER2 916/4885CRY2 1250/4885ALDH1A1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.